Angiotensin converting enzyme (ACE)inhibitors are commonly added for patients with reduced ejection fraction, recentMI, diabetes, or chronic kidney disease (CKD), but should be initiated cautiouslywith close monitoring of renal function and electrolytes, particularly in thosewith hemodynamic instability [34]. The gene discussed is ACE; the disease is chronic kidney disease.